Becker's Healthcare October 23, 2024
Alexandra Murphy

Novo Nordisk has requested that the FDA prohibit compounding pharmacies from producing unapproved versions of its popular weight loss and diabetes drugs, Wegovy and Ozempic, CNBC reported Oct. 23.

The pharmaceutical company argues that the active ingredient in both drugs, semaglutide, is too complex for compounders to safely replicate. The move follows Novo Nordisk’s yearlong battle against clinics and pharmacies that manufacture and sell cheaper, unapproved versions of semaglutide amid shortages of the branded drugs in the...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
Rare Disease Biotech Zevra Therapeutics to Sell FDA Drug Review Fast Pass for $150M
AI Accelerates Discovery of Genes Linked to Neurodevelopmental Disorders
A new era of Made in America drug manufacturing
Eli Lilly to invest $27B in manufacturing
Follow the Money: 3D Spatial Biology, AI-Powered Imaging Biomarkers, More

Share This Article